BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits.

February 20, 2024) - BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”), is issuing this news release to expand on and clarify its news release issued February 15

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”)

Everest Medicines ‘s licensing partner, Venatorx Pharmaceuticals announced that The New England Journal of Medicine published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections, including acute pyelonephritis.

Ono Pharmaceutical Co., Ltd. announced that it has entered into a research collaboration agreement with InveniAI® LLC, to identify novel therapeutic targets by leveraging cutting-edge InveniAI’s artificial intelligence and machine learning.

On February 19, 2024, the Journal of American Medical Association•Neurology published online the key findings of a phase III clinical study investigating Sanbexin® sublingual tablets for the treatment of acute ischemic stroke.